Eicosapentaenoic acid biosynthesis pathway

The **eicosapentaenoic acid biosynthesis pathway** is a sequence of enzymatic reactions in certain eukaryotes (such as microalgae, fungi, and some animals) and prokaryotes (notably marine bacteria) leading to the synthesis of **eicosapentaenoic acid (EPA)**, a crucial omega-3 polyunsaturated fatty acid. In eukaryotes, EPA biosynthesis typically proceeds via the aerobic “Δ6-desaturase pathway,” which catalyzes desaturation and elongation reactions on precursor C18 fatty acids like alpha-linolenic acid, ultimately producing EPA through specific elongases and desaturases[1][2]. Alternative pathways such as the “Δ9 elongase pathway” are present in some protists and microalgae[2]. In marine bacteria and certain microalgae like Thraustochytrids, an anaerobic **polyketide synthase (PKS) pathway** synthesizes EPA using iterative condensation, reduction, and dehydration reactions similar to secondary metabolite biosynthesis[1][3][4]. EPA produced by these pathways is integral to membrane fluidity, signaling molecule synthesis (e.g., eicosanoids and resolvins), and has important physiological implications for human health, particularly in cardiovascular and inflammatory diseases[6]. However, as a **pathway**, and not a single molecular target, it is not directly “targetable” in the context of a drug discovery receptor, enzyme, or transporter, though individual enzymes within it can be targets for metabolic engineering, supplementation, or regulatory intervention[3][4].\n\n**Note:** \nThis entry represents a metabolic pathway (a series of enzymatic reactions), not a discrete molecule or “target” in the therapeutic sense. For structured information about drug targets, it is recommended to refer to individual enzymes in the pathway, such as Δ5-desaturase, Δ6-desaturase, elongases, or polyketide synthase complexes[1][2][3].

Other names

EPA biosynthesis pathwayn-3 polyunsaturated fatty acid biosynthetic pathway